Hansa Biopharma AB (publ) (HNSA) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hansa Biopharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.335 -- 00:00:04.842 Good day, and welcome to the HANSA Biopharma interim results and Q1 earnings conference 00:00:04.842 -- 00:00:08.989 call. All participants will be in listen-only mode. 00:00:08.989 -- 00:00:12.815 Should you need assistance, please see the conference specialist by pressing the star 00:00:12.815 -- 00:00:15.379 key followed by zero. 00:00:15.379 -- 00:00:18.865 After today's presentation, there will be an opportunity to ask questions. 00:00:18.865 -- 00:00:22.210 To ask a question, you may press star, then one on your telephone keypad. 00:00:22.210 -- 00:00:25.916 To withdraw your question, please press star, then two. 00:00:25.916 -- 00:00:28.735 Please note, this event is being recorded. 00:00:28.735 -- 00:00:32.499 And now I turn the conference over to Peter Nicklin, Chairman of the Board, Hansa Biopharma. 00:00:32.499 -- 00:00:34.799 Please go ahead. 00:00:35.462 -- 00:00:38.305 Good afternoon and good morning, everybody. 00:00:38.305 -- 00:00:43.451 Welcome to the Hansa Biopharma conference call to review our Q1 results for 00:00:43.451 -- 00:00:45.451 2025. 00:00:46.294 -- 00:00:49.738 I'm Peter Nicklin, Chairman of the Board of Hansa Biopharma. 00:00:49.738 -- 00:00:55.164 You'll recollect in June this year, I actually reached my third year anniversary 00:00:55.164 -- 00:01:00.285 as Chairman of the Board. Joining me today is Adam Ballantyne, Chief Financial 00:01:00.285 -- 00:01:06.033 Officer, Hito Kaufmann, our Chief R&D Officer, and René 00:01:06.033 -- 00:01:10.279 Lucander, our newly appointed CEO. 00:01:10.279 -- 00:01:15.407 Before we turn to the Q1 results, you are most likely aware that earlier 00:01:15.407 -- 00:01:21.235 today we announced the departure of Sölden Tolstoy, CEO of Hansa Biopharma, 00:01:21.235 -- 0...